Review of a promising new agent--pemetrexed disodium.

@article{PazAres2003ReviewOA,
  title={Review of a promising new agent--pemetrexed disodium.},
  author={Luis Paz-Ares and Susana Bezares and Jose Matias Tabernero and Daniel Castellanos and Hern{\'a}n Cort{\'e}s-Fun{\'e}s},
  journal={Cancer},
  year={2003},
  volume={97 8 Suppl},
  pages={2056-63}
}
Pemetrexed disodium (ALIMTa, [pemetrexed], LY231514; Eli Lilly and Company; Indianapolis, IN), a novel antifolate antimetabolite with multiple enzyme targets involved in both pyrimidine and purine synthesis, has entered clinical trials due to its favorable pleclinical profile. Many studies utilizing the drug, as a single or combination agent, are currently ongoing, including Phase III trials in mesothelioma, nonsmall cell lung carcinoma (NSCLC) and pancreatic cancer. Promising feasibility and… CONTINUE READING
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…